Studies Addressing Rare Neurodegenerative Diseases including ALS

The Food and Drug Administration (FDA) is announcing a funding opportunity for studies addressing rare neurodegenerative diseases, including ALS. The purpose of this funding opportunity is to support studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. Key aspects of this opportunity include: • The FDA expects to address critical knowledge gaps and exert a significant impact on rare neurodegenerative diseases. • The funding opportunity is open to various types of entities, including state governments, county governments, city or township governments, special district governments, independent school districts, public housing authorities, Native American tribal organizations, small businesses, and non-profits. • The funding instrument for this opportunity is a grant. • The estimated number of awards is 10.